A defined commensal consortium elicits CD8 T cells and anti-cancer immunity

Nature

Volumn 565, Issue 7741, 2019, Pages 600-605

  Tanoue, Takeshi ^a,b,c   Morita, Satoru ^a   Plichta, Damian R ^d   Skelly, Ashwin N ^a   Suda, Wataru ^c,e,f   Sugiura, Yuki ^a   Narushima, Seiko ^a,c   Vlamakis, Hera ^d   Motoo, Iori ^c   Sugita, Kayoko ^a   Shiota, Atsushi ^a,b   Takeshita, Kozue ^a   Yasuma Mitobe, Keiko ^a   Riethmacher, Dieter ^g   Kaisho, Tsuneyasu ^h   Norman, Jason M ⁱ   Mucida, Daniel ^j   Suematsu, Makoto ^a   Yaguchi, Tomonori ^a   Bucci, Vanni ^k   Inoue, Takashi ^l   Kawakami, Yutaka ^a   Olle, Bernat ⁱ   Roberts, Bruce ⁱ   Hattori, Masahira ^c,e,f   Xavier, Ramnik J ^d,m   Atarashi, Koji ^a,b,c   Honda, Kenya ^a,b,c   more..

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c Institute of Physical and Chemical Research   (Japan)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e WASEDA UNIVERSITY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g NAZARBAYEV UNIVERSITY   (Kazakhstan)

^h WAKAYAMA MEDICAL UNIVERSITY   (Japan)

ⁱ Vedanta Biosciences   (United States)

^j ROCKEFELLER UNIVERSITY   (United States)

^k University of Massachusetts Dartmouth   (United States)

^l CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CD8ALPHA ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2.43; MONOCLONAL ANTIBODY 9H10; MONOCLONAL ANTIBODY J43; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; ALPHA E INTEGRINS; ALPHA INTEGRIN; HLA ANTIGEN CLASS 1; LEUKOCYTE ANTIGEN;

CELL COMPONENT; DIGESTIVE SYSTEM; GENE EXPRESSION; IMMUNITY; INHIBITOR; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROORGANISM; PHYSIOLOGY; TUMOR;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; CD8+ T LYMPHOCYTE; COMMENSAL; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HOST RESISTANCE; INTERFERON PRODUCTION; INTESTINE FLORA; LISTERIOSIS; MALE; MC-38 CELL LINE; MELANOMA; MELANOMA CELL; MICROBIAL CONSORTIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; BACTERIUM; BIOSYNTHESIS; CLASSIFICATION; CYTOLOGY; DRUG SCREENING; FECES; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; LISTERIA MONOCYTOGENES; METABOLISM; MICROBIOLOGY; NORMAL HUMAN; PATHOLOGY; SYMBIOSIS; TUMOR CELL LINE;

BACTERIA (MICROORGANISMS); LISTERIA MONOCYTOGENES; MUS;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD; BACTERIA; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HEALTHY VOLUNTEERS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTEGRIN ALPHA CHAINS; INTERFERON-GAMMA; LISTERIA MONOCYTOGENES; LISTERIOSIS; MALE; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; SYMBIOSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85060753155     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-019-0878-z     Document Type: Article

References (43)

1. Mimee, M., Citorik, R. J. & Lu, T. K. Microbiome therapeutics — advances and challenges. Adv. Drug Deliv. Rev. 105, 44–54 (2016).
2. Kim, S., Covington, A. & Pamer, E. G. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. Immunol. Rev. 279, 90–105 (2017).
3. El Hage, R., Hernandez-Sanabria, E. & Van de Wiele, T. Emerging trends in “smart probiotics”: functional consideration for the development of novel health and industrial applications. Front. Microbiol. 8, 1889 (2017).
4. Blander, J. M., Longman, R. S., Iliev, I. D., Sonnenberg, G. F. & Artis, D. Regulation of inflammation by microbiota interactions with the host. Nat. Immunol. 18, 851–860 (2017).
5. Atarashi, K. et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500, 232–236 (2013).
6. Faith, J. J., Ahern, P. P., Ridaura, V. K., Cheng, J. & Gordon, J. I. Identifying gut microbe–host phenotype relationships using combinatorial communities in gnotobiotic mice. Sci. Transl. Med. 6, 220ra11 (2014).
7. + regulatory T cells. Science 349, 993–997 (2015).
8. Atarashi, K. et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell 163, 367–380 (2015).
9. Tan, T. G. et al. Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice. Proc. Natl Acad. Sci. USA 113, E8141–E8150 (2016).
10. Ichinohe, T. et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl Acad. Sci. USA 108, 5354–5359 (2011).
11. Thackray, L. B. et al. Oral antibiotic treatment of mice exacerbates the disease severity of multiple flavivirus infections. Cell Rep. 22, 3440–3453 (2018).
12. Spranger, S., Sivan, A., Corrales, L. & Gajewski, T. F. Tumor and host factors controlling antitumor immunity and efficacy of cancer immunotherapy. Adv. Immunol. 130, 75–93 (2016).
13. Bhatt, A. P., Redinbo, M. R. & Bultman, S. J. The role of the microbiome in cancer development and therapy. CA Cancer J. Clin. 67, 326–344 (2017).
14. Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G. & Gajewski, T. F. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 359, 1366–1370 (2018).
15. Park, C. O. & Kupper, T. S. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat. Med. 21, 688–697 (2015).
16. H 1 cell induction and inflammation. Science 358, 359–365 (2017).
17. + dendritic cells in cytotoxic T cell immunity. Science 322, 1097–1100 (2008).
18. Ohta, T. et al. Crucial roles of XCR1-expressing dendritic cells and the XCR1–XCL1 chemokine axis in intestinal immune homeostasis. Sci. Rep. 6, 23505 (2016).
19. Joeris, T., Müller-Luda, K., Agace, W. W. & Mowat, A. M. Diversity and functions of intestinal mononuclear phagocytes. Mucosal Immunol. 10, 845–864 (2017).
20. Satpathy, A. T. et al. Notch2-dependent classical dendritic cells orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens. Nat. Immunol. 14, 937–948 (2013).
21. + T cells with enhanced protective function. Immunity 40, 747–757 (2014).
22. Foulds, K. E. et al. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J. Immunol. 168, 1528–1532 (2002).
23. Gao, J. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–404 (2016).
24. Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120–1133 (2017).
25. Yang, J. C. & Perry-Lalley, D. The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J. Immunother. 23, 177–183 (2000).
26. Cooper, Z. A. et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol. Res. 2, 643–654 (2014).
27. V600E cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544–552 (2009).
28. Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).
29. Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
30. Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).
31. Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).
32. Frankel, A. E. et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 19, 848–855 (2017).
33. Johansson, M. E. et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc. Natl Acad. Sci. USA 105, 15064–15069 (2008).
34. Nishijima, S. et al. The gut microbiome of healthy Japanese and its microbial and functional uniqueness. DNA Res 23, 125–133 (2016).
35. Miyajima, M. et al. Metabolic shift induced by systemic activation of T cells in PD-1-deficient mice perturbs brain monoamines and emotional behavior. Nat. Immunol. 18, 1342–1352 (2017).
36. Hu, S. et al. Targeted metabolomic analysis of head and neck cancer cells using high performance ion chromatography coupled with a Q exactive HF mass spectrometer. Anal. Chem. 87, 6371–6379 (2015).
37. Oka, M. et al. Arl8b is required for lysosomal degradation of maternal proteins in the visceral yolk sac endoderm of mouse embryos. J. Cell Sci. 130, 3568–3577 (2017).
38. Lloyd-Price, J. et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature 550, 61–66 (2017).
39. The Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16, 276–289 (2014).
40. Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1897 (2016).
41. Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352, 565–569 (2016).
42. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
43. Li, J. et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 32, 834–841 (2014).